ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Busin... ( ADDISON Texas March 28 /- ULURU I...)

HOME >> MEDICINE >> NEWS

ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update

Date:3/28/2008

ADDISON, Texas, March 28 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has scheduled a conference call to discuss the fourth quarter 2007 financial results and provide a general business update on Tuesday, April 1, 2008 at 10:00 a.m. Eastern time.

To participate in the conference call, please dial (800) 357-0498 for international callers dial (850) 429-1388 (access code 9285#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast a replay of the call will be available starting on April 1, 2008 two hours following the end of the call until April 8, 2008 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (800) 695-0697 for international callers dial (402) 220-1472 (access code 9285#).

Interested investors and others may also listen to the conference call replay through our Internet webcast, which may be accessed by visiting our website at http://www.uluruinc.com and clicking on the "Investor Relations" icon.

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other report
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets

Post Your Comments:

(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s

(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i

(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud

(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic

(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel

Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2 Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2 Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2 Health News:Potential new 'twist' in breast cancer detection 2 Health News:Potential new 'twist' in breast cancer detection 3

[0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children [0] Statement from AAHSA CEO Larry Minnix on the Failure of the Thune Amendment [0] BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use [0] Natural Products Association Issues Statement on DEA's Steroid Classification Action [0] Potential new 'twist' in breast cancer detection

...Student Medical Insurance Strengthens Offerings to... Baltimore, MD. (Vocus) May 4, 2009 -- MEDEX Gl...mpleted the acquisition of CMI Insurance, formerly...p. , ,"We have worked hard on this deal and a...

...ge Growth and Effective Expense Management , , Co..., Ala., May 4 HealthSouth Corporation (NYSE: HL...he first quarter ended March 31, 2009. The results...or an increase of 2.3%. This increase was driven b...

...mer, valley businesses shed their business attire ... all in the spirit of raising money for United Cer...rving children and adults with disabilities. This...nother date if preferred. , , With the economy ...

...t Society of American Gastroenterological and Endo...EMENTE, Calif., May 4 USGI Medical, Inc. (USGI), ...(TM) (IOP) was featured in three podium sessions a...ona. , , Dr. Frank Borao and separately Dr. Garth...

...sSource, the nation,s leading supplier of replacem...as won its fourth straight Team NEO award. Team N...both employee and revenue growth in Northern Ohio ... said President & CEO A. Ray Dalton. "Despite...

...cretary of the Commonwealth Pedro A. Cortes today ...d of Nursing. , , "The State Board of Nursing,s d...fare of the residents of Pennsylvania has helped p...s of education and conduct for the benefit of the ...

MEDEX Acquires CMI Insurance HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 Valley Businesses Shedding Their Suits to Go Casual for a Cause Studies Report Use of USGI Medical's Incisionless Operating Platform(TM) (IOP) in Numerous Incisionless Surgical Procedures PartsSource Named Team NEO Winner for 2009 Pennsylvania Secretary Cortes Marks 100th Anniversary of State Board of Nursing

(Date:12/4/2009)...orkers Ensure Emergency Deliveries are Transported...yed by the Philadelphia chapter of the American Re...t the unfair labor conditions that they endure tha...y at risk. More than 100 employees went on strike...ues were ignored by their employer. ,, Red Cross m...

(Date:12/4/2009)...HAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (O...first patient has been enrolled in the company,s P...zerland for use of Oxycyte(TM) emulsion in traumat...rfluorocarbon (PFC) therapeutic oxygen carrier. ,,...ing the outcome of patients with severe TBI. We ho...

(Date:12/4/2009)...NNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Ame... countermeasures against biological and chemical t...ta from the Company,s anthrax vaccine program show...tigen (rPA) based anthrax vaccine is structurally ...ratures up to and including 55 degrees C. The dat...

Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2 Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5 Moderate amounts of protein per meal found best for building muscle 10531 1 Moderate amounts of protein per meal found best for building muscle 10531 2 Treat Kids to a Safe Halloween 60105 1 Treat Kids to a Safe Halloween 60105 2 Plastic Surgeons to Discuss Cleavage Rejuvenation Do It Yourself Lasers and Other Hot Topics with the Media 60102 1 Plastic Surgeons to Discuss Cleavage Rejuvenation Do It Yourself Lasers and Other Hot Topics with the Media 60102 2

[0] Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions [0] Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland [0] PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop

...Shows Increased Muscle and Blood Vessel Formation ...NRISE, Fla., July 24 Results of a,preclinical stu...o express,stromal derived factor-1(alpha) protein ...rats, which suggest improved heart function, were ...he International Society for,Magnetic Resonance in...

... Program Speeds Oncology Patient Accrual, DENVER,...Organization (RMO), has contracted with five leadi...d site management services for their,clinical tria...y. The new,trials include the following disease in...static Breast Cancer, Metastatic Sarcoma, Chronic ...

Other Medicine Technology:Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2 Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3 Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4 Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5 Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6 Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2

Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials

Contour Design Eyelid Implants (Gold)

Symblepharon Ring (medium)

Ptose-Up Ptosis Sling (3mm)

Zone Quick Tear Volume Measurement

Medicine Products:

Contour Design Eyelid Implants (Gold)Symblepharon Ring (medium)Ptose-Up Ptosis Sling (3mm)Zone Quick Tear Volume Measurement

ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Busin...( ADDISON Texas March 28 /- ULURU I...),Health